Success Metrics

Clinical Success Rate
84.2%

Based on 208 completed trials

Completion Rate
84%(208/247)
Active Trials
17(6%)
Results Posted
55%(114 trials)
Terminated
39(13%)

Phase Distribution

Ph not_applicable
37
13%
Ph phase_1
30
10%
Ph early_phase_1
8
3%
Ph phase_2
71
24%
Ph phase_3
54
18%
Ph phase_4
81
28%

Phase Distribution

38

Early Stage

71

Mid Stage

135

Late Stage

Phase Distribution281 total trials
Early Phase 1First-in-human
8(2.8%)
Phase 1Safety & dosage
30(10.7%)
Phase 2Efficacy & side effects
71(25.3%)
Phase 3Large-scale testing
54(19.2%)
Phase 4Post-market surveillance
81(28.8%)
N/ANon-phased studies
37(13.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.6%

208 of 255 finished

Non-Completion Rate

18.4%

47 ended early

Currently Active

17

trials recruiting

Total Trials

293

all time

Status Distribution
Active(17)
Completed(208)
Terminated(47)
Other(21)

Detailed Status

Completed208
Terminated39
unknown21
Recruiting13
Withdrawn8
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
293
Active
17
Success Rate
84.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 18 (2.8%)
Phase 130 (10.7%)
Phase 271 (25.3%)
Phase 354 (19.2%)
Phase 481 (28.8%)
N/A37 (13.2%)

Trials by Status

unknown217%
recruiting134%
terminated3913%
completed20871%
active_not_recruiting41%
withdrawn83%

Recent Activity

Clinical Trials (293)

Showing 20 of 293 trialsScroll for more
NCT03109288Phase 1

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Recruiting
NCT06399835Phase 4

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
NCT07444424Phase 1

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants

Active Not Recruiting
NCT06657209Phase 4

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Recruiting
NCT02592317Phase 1

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Active Not Recruiting
NCT04843046Phase 2

Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention

Completed
NCT02133625Phase 1

A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors

Completed
NCT06246799Phase 3

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Recruiting
NCT06851962Phase 4

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Active Not Recruiting
NCT03866408Early Phase 1

Insulin Regulation of Lipolysis and Lipolysis Proteins

Recruiting
NCT05305287Phase 4

Quantifying Hepatic Mitochondrial Fluxes in Humans

Recruiting
NCT05028140Phase 3

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Recruiting
NCT05107765Phase 1

Effects of Pioglitazone on Stress Reactivity and Alcohol Craving

Completed
NCT05838287Phase 4

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

Recruiting
NCT02969798Not Applicable

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Recruiting
NCT02879409Not Applicable

HbA1c Variability in Type II Diabetes

Active Not Recruiting
NCT03471117Phase 4

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Recruiting
NCT01225081Phase 3

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients

Completed
NCT04501406Phase 2

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Recruiting
NCT01028963Phase 2

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

Completed

Drug Details

Intervention Type
DRUG
Total Trials
293